The abstract reports selective effects on dopamine, adrenaline, and noradrenaline but no impact on serotonin or histamine systems. This selectivity pattern is unexplained and understanding it could reveal novel therapeutic targets for neurotransmitter modulation. Gap type: unexplained_observation Source paper: Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. (2021, Med Res Rev, PMID:34106485)
Landscape Summary: Why does Atremorine selectively affect dopaminergic neurotransmitters while sparing serotonin and histamine? is a 0.76 priority gap in neuropharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why does Atremorine selectively affect dopaminergic neurotransmitters while sparing serotonin and histamine? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: